AA
ENGNW icon

AQR Arbitrage’s enGene Therapeutics Warrants ENGNW Stock Holding History

AQR Arbitrage’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-127,339
Closed -$108K – 618
2023
Q4 		$108K Buy
+127,339
New +$97.9K ﹤0.01% 381

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

AQR Arbitrage's ENGNW Position: Q1 2024 in Review

AQR Arbitrage sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2024, closing a stake of 127,339 shares — an estimated $108K sold.

AQR Arbitrage first reported a position in ENGNW in Q4 2023 and held it in 1 quarter. The position peaked at $108K in Q4 2023. 16 funds tracked by Wall St. Rank hold ENGNW as of Q1 2024.

  • AQR Arbitrage reported no remaining enGene Therapeutics Warrants position as of Q1 2024 after selling out during the quarter.
  • AQR Arbitrage sold 127,339 enGene Therapeutics Warrants shares in Q1 2024, an estimated $108K.
  • AQR Arbitrage first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 1 quarter.
  • AQR Arbitrage's enGene Therapeutics Warrants position peaked at $108K in Q4 2023.
  • 16 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2024.

Based on AQR Arbitrage's 13F filing for Q1 2024, filed 15 May 2024.